RA CAPITAL MANAGEMENT, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001346824

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q4 2024 · 89 positions · Total reported value $7.51B · Top-10 concentration 57.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.4% · 15 new · 12 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.6% · vs SPY -15.8% · Prev Value $11.51B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.6% · vs SPY -3.7% · Latest Value $9.72B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q4 2024 13F filing, RA CAPITAL MANAGEMENT, L.P. disclosed 89 equity positions with a combined reported value of $7.51B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 57.6% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2024 were ASND ($1.39B), PCVX ($711.30M), JANX ($554.98M). By sector, the heaviest allocations are Health Care 84.3%, Industrials 0.9%. Versus the prior quarter, allocation shifted toward Industrials (+0.9pp), Other (+0.9pp) and away from Consumer Discretionary (-2.2pp).

Versus the prior quarter, RA CAPITAL MANAGEMENT, L.P. opened 15 new positions, trimmed 12 and fully exited 11, a turnover rate of 38.4% of positions. The portfolio's overlap with the prior quarter was 73% of names.

The largest new positions opened in Q4 2024 were SEPN ($160.21M), XBI ($110.62M), TXG ($47.09M).

Of the 11 positions fully exited versus the prior quarter, the largest were BIIB ($229.59M), CGON ($52.73M), ANRO ($23.74M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2024)

  • SEPN SEPTERNA INC · $160.21M
  • XBI SPDR SERIES TRUST · $110.62M
  • TXG 10X GENOMICS INC · $47.09M
  • KURA KURA ONCOLOGY INC · $38.77M
  • ZLAB ZAI LAB LTD · $33.92M
  • NRIX NURIX THERAPEUTICS INC · $25.12M
  • EYPT EYEPOINT INC · $23.70M
  • CBLL CERIBELL INC · $21.34M

Fully Exited (vs previous quarter)

  • BIIB BIOGEN INC · prev qtr: $229.59M
  • CGON CG ONCOLOGY INC · prev qtr: $52.73M
  • ANRO ALTO NEUROSCIENCE INC · prev qtr: $23.74M
  • NUVL NUVALENT INC · prev qtr: $18.03M
  • TNYA TENAYA THERAPEUTICS INC · prev qtr: $13.48M
  • CRVO CERVOMED INC · prev qtr: $11.93M
  • ADGM Adagio Med Hldgs Inc Com · prev qtr: $3.44M
  • MGX METAGENOMI THERAPEUTICS INC · prev qtr: $2.83M

Insider Transactions (Form 4)

Latest RA CAPITAL MANAGEMENT, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 164,891 $16.00 SEC filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 2,335,109 $16.00 SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 1,331,080 — SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 3,144,858 — SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 263,911 $14.92 SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 189,909 $14.23 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 107,170 $3.36 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 451,998 $3.36 SEC filing

All insider transactions →

Fund Profile

RA Capital Management is a Boston-based investment firm founded by Peter Kiernan, specializing in healthcare-focused investments with a long-term, value-oriented approach.

Investment Approach

Focuses on healthcare sector investments

Long-term, value-oriented strategy

Deep fundamental research and analysis

Asset Classes & Strategy

Primarily invests in public equities

Also manages private investments in healthcare companies

Concentrated portfolio approach with significant positions in healthcare companies

Key Personnel

Peter Kiernan: Founder and portfolio manager

Team of experienced investment professionals with healthcare expertise

Notable Facts

Founded in 2002

Manages approximately $16.4 billion in assets

Files SEC Form 13F for US equity positions

This profile is based on publicly available information and should not be considered as official disclosure from the firm.

Sector Allocation

Health Care 84.3%
Materials 0.1%
Other 14.1%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 10.11M $1.39B 18.53%
18.53%
Add
2 8.69M $711.30M 9.47%
9.47%
Hold
3 10.37M $554.98M 7.39%
7.39%
Add
4 6.08M $340.61M 4.53%
4.53%
Hold
5 7.51M $244.28M 3.25%
3.25%
Hold
6 8.91M $237.87M 3.17%
3.17%
Hold
7 8.85M $227.32M 3.02%
3.02%
Add
8 18.20M $225.16M 3.00%
Form 4 · 1 →
3.00%
Hold
9 2.79M $213.76M 2.85%
2.85%
Add
10 6.30M $183.22M 2.44%
2.44%
Hold
11 7.00M $160.21M 2.13%
2.13%
New
12 6.38M $150.34M 2.00%
2.00%
Hold
13 10.64M $147.86M 1.97%
1.97%
Add
14 3.74M $128.68M 1.71%
1.71%
Reduce
15 6.96M $121.17M 1.61%
1.61%
Hold
16 4.18M $120.64M 1.61%
Form 4 · 3 →
1.61%
Hold
17 10.86M $114.58M 1.52%
1.52%
Hold
18 14.18M $110.85M 1.48%
1.48%
Hold
19 1.23M $110.62M 1.47%
1.47%
New
20 30.01M $106.23M 1.41%
1.41%
Reduce
21 9.85M $99.32M 1.32%
1.32%
Hold
22 1.00M $84.61M 1.13%
1.13%
Hold
23 1.77M $82.05M 1.09%
1.09%
Reduce
24 5.76M $72.92M 0.97%
0.97%
Reduce
25 1.57M $71.10M 0.95%
0.95%
Reduce
26 4.85M $59.72M 0.80%
0.80%
Hold
27 761.96K $58.64M 0.78%
0.78%
Hold
28 31.42M $56.55M 0.75%
Form 4 · 4 →
0.75%
Hold
29 7.73M $52.22M 0.69%
0.69%
Reduce
30 2.54M $51.49M 0.69%
0.69%
Hold
31 8.34M $50.21M 0.67%
0.67%
Hold
32 10.23M $48.08M 0.64%
0.64%
Hold
33 3.28M $47.09M 0.63%
0.63%
New
34 6.69M $46.81M 0.62%
0.62%
Hold
35 5.11M $45.64M 0.61%
0.61%
Hold
36 39.65M $44.01M 0.59%
Form 4 · 1 →
0.59%
Add
37 1.52M $41.15M 0.55%
0.55%
Reduce
38 1.87M $40.69M 0.54%
0.54%
Reduce
39 10.69M $40.51M 0.54%
0.54%
Hold
40 3.58M $40.24M 0.54%
0.54%
Reduce
41 4.45M $38.77M 0.52%
0.52%
New
42 1.35M $34.62M 0.46%
0.46%
Hold
43 1.30M $33.92M 0.45%
0.45%
New
44 8.80M $30.62M 0.41%
0.41%
Hold
45 1.09M $29.37M 0.39%
0.39%
Add
46 1.51M $27.85M 0.37%
0.37%
Hold
47 10.81M $26.90M 0.36%
0.36%
Hold
48 14.93M $25.68M 0.34%
0.34%
Hold
49 4.56M $25.42M 0.34%
0.34%
Reduce
50 1.33M $25.12M 0.33%
0.33%
New

FAQ

What did RA CAPITAL MANAGEMENT, L.P. buy in 2024-Q4?

In its 2024-Q4 13F filing, RA CAPITAL MANAGEMENT, L.P. reported 89 equity positions worth $7.51B in aggregate; its largest disclosed positions were ASND ($1.39B), PCVX ($711.30M), JANX ($554.98M).

How large is RA CAPITAL MANAGEMENT, L.P.'s portfolio?

RA CAPITAL MANAGEMENT, L.P. reported $7.51B of long equity holdings across 89 positions as of 2024-Q4. Top-10 holdings account for 57.6% of reported value.

What is RA CAPITAL MANAGEMENT, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/ra-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →